Literature DB >> 18816618

Histologic associations and long-term cancer risk in columnar cell lesions of the breast: a retrospective cohort and a nested case-control study.

Fouad I Boulos1, William D Dupont, Jean F Simpson, Peggy A Schuyler, Melinda E Sanders, Marcia E Freudenthal, David L Page.   

Abstract

BACKGROUND: Mammary columnar cell lesions with atypia have been receiving increased scrutiny in view of their association with atypical hyperplasia (AH) and carcinoma. However, the few retrospective outcome studies performed have failed to establish an increased risk for recurrence or carcinoma on long-term follow-up.
METHODS: The authors evaluated the overall cancer risk for 1261 biopsies with columnar cell lesions (CCL) in 4569 women from the Nashville Breast Cohort who were biopsied between 1969 and 1988. On the basis of Schnitt and Vincent-Salomon's classification, they also classified 229 biopsies with CCL into 3 categories: without hyperplasia or atypia, with hyperplasia lacking atypia, and with atypia. By using a nested case-control design, they compared the risks of invasive cancer associated with these 3 categories.
RESULTS: A 2- to 3-fold increase in the occurrence of AH in the presence of CCL versus in their absence (P< .005) was observed. Relative risk of invasive breast cancer for women with both AH and CCL compared with those with AH alone did not differ significantly (risk ratio [RR]=1.55; P= .29). The presence of CCL alone was associated with a mild increase in the overall cancer risk (RR=1.47; P= .05). In the nested case-control study, no significant risk difference was observed among the 3 categories of CCL.
CONCLUSIONS: The authors observed a positive association between CCL and AH. The possibility that CCL by themselves significantly elevate breast cancer risk is not well supported. However, a finding of CCL on benign breast biopsy may indicate the presence of AH, a more worrisome lesion.

Entities:  

Mesh:

Year:  2008        PMID: 18816618      PMCID: PMC3121952          DOI: 10.1002/cncr.23873

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  39 in total

1.  Treatment selection in primary breast cancer. Pathologic considerations.

Authors:  H S Gallager
Journal:  AJR Am J Roentgenol       Date:  1976-01       Impact factor: 3.959

2.  Flat epithelial atypia (DIN 1a, atypical columnar change): an underdiagnosed entity very frequently coexisting with lobular neoplasia.

Authors:  S Leibl; P Regitnig; F Moinfar
Journal:  Histopathology       Date:  2007-06       Impact factor: 5.087

3.  Comparative Studies of Cancerous Versus Noncancerous Breasts.

Authors:  F W Foote; F W Stewart
Journal:  Ann Surg       Date:  1945-02       Impact factor: 12.969

4.  Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853.

Authors:  N Bijker; J L Peterse; L Duchateau; J P Julien; I S Fentiman; C Duval; S Di Palma; J Simony-Lafontaine; I de Mascarel; M J van de Vijver
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

5.  Atypical cystic lobule of the breast: an early stage of low-grade ductal carcinoma in-situ.

Authors:  T Oyama; K Iijima; H Takei; J Horiguchi; Y Iino; T Nakajima; F Koerner
Journal:  Breast Cancer       Date:  2000       Impact factor: 4.239

6.  Breast cancer risk associated with estrogen receptor expression in epithelial hyperplasia lacking atypia and adjacent lobular units.

Authors:  Helenice Gobbi; William D Dupont; Fritz F Parl; Peggy A Schuyler; W Dale Plummer; Sandra J Olson; David L Page
Journal:  Int J Cancer       Date:  2005-02-20       Impact factor: 7.396

7.  [Diagnosis of flat epithelial atypia (FEA) after stereotactic vacuum-assisted biopsy (VAB) of the breast: What is the best management: systematic surgery for all or follow-up?].

Authors:  N David; C Labbe-Devilliers; D Moreau; D Loussouarn; L Campion
Journal:  J Radiol       Date:  2006-11

8.  Long-term risk of breast cancer in women with fibroadenoma.

Authors:  W D Dupont; D L Page; F F Parl; C L Vnencak-Jones; W D Plummer; M S Rados; P A Schuyler
Journal:  N Engl J Med       Date:  1994-07-07       Impact factor: 91.245

9.  A prospective study of the development of breast cancer in 16,692 women with benign breast disease.

Authors:  C L Carter; D K Corle; M S Micozzi; A Schatzkin; P R Taylor
Journal:  Am J Epidemiol       Date:  1988-09       Impact factor: 4.897

10.  Assessment of lesions coexisting with various grades of ductal intraepithelial neoplasia of the breast.

Authors:  Gary L Bratthauer; Fattaneh A Tavassoli
Journal:  Virchows Arch       Date:  2004-02-19       Impact factor: 4.064

View more
  20 in total

1.  The "Got D'ViBE?" study: an inter-institutional project assessing vitamin D and mammographic breast density.

Authors:  Toni J Lewis; William D Dupont; Kathleen M Egan; Corey D Jones; Anthony C Disher; William R Riddle; Alecia Malin Fair
Journal:  J Health Care Poor Underserved       Date:  2010-02

2.  Surgical implications and variability in the use of the flat epithelial atypia diagnosis on breast biopsy specimens.

Authors:  Laura S Samples; Mara H Rendi; Paul D Frederick; Kimberly H Allison; Heidi D Nelson; Thomas R Morgan; Donald L Weaver; Joann G Elmore
Journal:  Breast       Date:  2017-05-03       Impact factor: 4.380

3.  Update 2010 of the German AGO Recommendations for the Diagnosis and Treatment of Early and Metastatic Breast Cancer - Chapter B: Prevention, Early Detection, Lifestyle, Premalignant Lesions, DCIS, Recurrent and Metastatic Breast Cancer.

Authors:  Christoph Thomssen; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2010-10-27       Impact factor: 2.860

4.  Flat epithelial atypia and risk of breast cancer: A Mayo cohort study.

Authors:  Samar M Said; Daniel W Visscher; Aziza Nassar; Ryan D Frank; Robert A Vierkant; Marlene H Frost; Karthik Ghosh; Derek C Radisky; Lynn C Hartmann; Amy C Degnim
Journal:  Cancer       Date:  2015-01-13       Impact factor: 6.860

5.  Morphological parameters of flat epithelial atypia (FEA) in stereotactic vacuum-assisted needle core biopsies do not predict the presence of malignancy on subsequent surgical excision.

Authors:  Simonetta Bianchi; Benedetta Bendinelli; Isabella Castellano; Quirino Piubello; Giuseppe Renne; Maria Grazia Cattani; Domenica Di Stefano; Giovanna Carrillo; Licia Laurino; Alessandra Bersiga; Carmela Giardina; Stefania Dante; Carla Di Loreto; Carmela Quero; Concetta Maria Antonacci; Domenico Palli
Journal:  Virchows Arch       Date:  2012-09-01       Impact factor: 4.064

Review 6.  Clinician's guide to imaging and pathologic findings in benign breast disease.

Authors:  Lonzetta Neal; Cindy L Tortorelli; Aziza Nassar
Journal:  Mayo Clin Proc       Date:  2010-03       Impact factor: 7.616

7.  Is the outcome at surgery different when flat epithelial atypia and lobular neoplasia are found in association at biopsy?

Authors:  Mona El Khoury; Lilia Maria Sanchez; Lucie Lalonde; Isabelle Trop; Julie David; Benoît Mesurolle
Journal:  Br J Radiol       Date:  2017-03-03       Impact factor: 3.039

8.  A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer.

Authors:  Geoffrey C Kabat; Joan G Jones; Neal Olson; Abdissa Negassa; Catherine Duggan; Mindy Ginsberg; Rita A Kandel; Andrew G Glass; Thomas E Rohan
Journal:  Cancer Causes Control       Date:  2010-01-19       Impact factor: 2.506

9.  Columnar cell lesions and subsequent breast cancer risk: a nested case-control study.

Authors:  Sarah A Aroner; Laura C Collins; Stuart J Schnitt; James L Connolly; Graham A Colditz; Rulla M Tamimi
Journal:  Breast Cancer Res       Date:  2010-08-06       Impact factor: 6.466

10.  Flat epithelial atypia: conservative management of patients without residual microcalcifications post-vacuum-assisted breast biopsy.

Authors:  Simone Schiaffino; Licia Gristina; Alessandro Villa; Simona Tosto; Francesco Monetti; Franca Carli; Massimo Calabrese
Journal:  Br J Radiol       Date:  2017-11-09       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.